Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Long-Term Deferred Tax (2023 - 2024)

Historic Long-Term Deferred Tax for Coeptis Therapeutics Holdings (COEP) over the last 2 years, with Q4 2024 value amounting to $25.6 million.

  • Coeptis Therapeutics Holdings' Long-Term Deferred Tax rose 1061.33% to $25.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $25.6 million, marking a year-over-year increase of 1061.33%. This contributed to the annual value of $25.6 million for FY2024, which is 1061.33% up from last year.
  • Latest data reveals that Coeptis Therapeutics Holdings reported Long-Term Deferred Tax of $25.6 million as of Q4 2024, which was up 1061.33% from $23.1 million recorded in Q4 2023.
  • Coeptis Therapeutics Holdings' Long-Term Deferred Tax's 5-year high stood at $25.6 million during Q4 2024, with a 5-year trough of $23.1 million in Q4 2023.